Latest Period
Q1 2026
Security Snapshot
Lunai Bioworks Inc. - Common Stock, par value $0.0001 per share (RENB) Institutional Ownership
CUSIP: 29350E104
13F Institutional Holders and Ownership History from Q4 2018 to Q1 2026
Institutions Reporting
1
Shares (Excl. Options)
632
Price
$0.41
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- RENB
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 632
- Total 13F value
- $258
- Portfolio coverage rank
- 0%
- Share change
- +159
- Value change
- +$65
- Number of holders
- 1
- Shares outstanding
- 226,664,950
- SEC-reported price per share
- $0.41
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RENB - Lunai Bioworks Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 29350E104.
- 1 institution reported positions in Q1 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 1 to 1 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $417 to $258.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1 institution filings for Q1 2026.
Security key
29350E104
Latest holder period
Q1 2026
13F holders
1
13D/G owners
1
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29350E104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
RENB
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| William Anderson Wittekind | 8% | -24% | $6,890,614 | 18,133,196 | 0% | William Anderson Wittekind | 09 Jul 2025 |
As of 31 Mar 2026, 1 institutional investors reported holding 632 shares of Lunai Bioworks Inc. - Common Stock, par value $0.0001 per share (RENB). This represents 0% of the company’s total 226,664,950 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
30
Latest
Q1 2026
Rows shown
1-25 of 30
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 632 | $258 | +$65 | $0.41 | 1 |
| 2025 Q4 | 473 | $417 | +$410 | $0.88 | 1 |
| 2025 Q3 | 5 | $7 | -$4,165,731 | $1.40 | 1 |
| 2025 Q2 | 14,426,097 | $4,167,462 | -$2,600,917 | $0.29 | 41 |
| 2025 Q1 | 22,011,689 | $11,955,928 | -$181,227 | $0.54 | 60 |
| 2024 Q4 | 22,130,549 | $18,494,017 | +$6,146,174 | $0.84 | 57 |
| 2024 Q3 | 14,761,228 | $7,133,507 | +$169,016 | $0.48 | 48 |
| 2024 Q2 | 14,157,443 | $24,775,363 | +$11,117,231 | $1.75 | 37 |
| 2024 Q1 | 7,245,406 | $19,200,126 | +$12,268,136 | $2.65 | 40 |
| 2023 Q4 | 2,572,614 | $8,156,630 | +$3,304,877 | $3.17 | 35 |
| 2023 Q3 | 1,488,192 | $6,652,555 | +$1,025,340 | $4.47 | 20 |
| 2023 Q2 | 1,849,727 | $1,126,647 | -$873,336 | $0.57 | 30 |
| 2023 Q1 | 3,303,933 | $3,023,286 | -$317,455 | $0.92 | 40 |
| 2022 Q4 | 3,630,699 | $3,739,039 | -$186,936 | $1.03 | 38 |
| 2022 Q3 | 3,770,390 | $6,824,610 | -$322,962 | $1.81 | 35 |
| 2022 Q2 | 3,939,159 | $7,601,528 | +$151,242 | $1.93 | 45 |
| 2022 Q1 | 2,604,770 | $21,490,710 | +$1,349,340 | $8.25 | 41 |
| 2021 Q4 | 2,470,884 | $18,009,948 | +$6,992,602 | $7.29 | 41 |
| 2021 Q3 | 1,518,637 | $10,217,810 | -$7,069,450 | $6.73 | 27 |
| 2021 Q2 | 2,668,374 | $13,262,947 | +$159,629 | $4.97 | 31 |
| 2021 Q1 | 2,712,365 | $9,595,115 | +$1,002,460 | $3.54 | 39 |
| 2020 Q4 | 2,446,048 | $7,222,222 | +$133,204 | $2.95 | 40 |
| 2020 Q3 | 2,381,325 | $8,536,220 | -$333,103 | $3.58 | 37 |
| 2020 Q2 | 2,469,200 | $10,397,463 | +$797,204 | $4.21 | 32 |
| 2020 Q1 | 2,286,020 | $6,854,756 | +$338,301 | $3.00 | 31 |